Glenmede Investment Management’s Dianthus Therapeutics DNTH Stock Holding History

Glenmede Investment Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$213K	Buy	+5,415	New	+$138K	﹤0.01%	1244

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Glenmede Investment Management's DNTH Position: Q3 2025 in Review

Glenmede Investment Management opened a new position in Dianthus Therapeutics (DNTH) in Q3 2025: 5,415 shares worth $213K. The stake represents ﹤0.01% of the portfolio and ranks #1244 among its holdings.

140 funds tracked by Wall St. Rank hold DNTH as of Q3 2025.

Glenmede Investment Management held 5,415 shares of Dianthus Therapeutics worth $213K as of Q3 2025.
Dianthus Therapeutics was a new Glenmede Investment Management position in Q3 2025.
Dianthus Therapeutics made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #1244 holding.
140 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.